“Tecnovax: National Biotechnology Company with 20 Years of Experience in Animal Vaccines”

Tecnovax is a national capital biotechnology company with 20 years of experience in the activity. Its main activity is the development, production and packaging of vaccines for the prevention of infectious diseases in animal health, which are marketed both in the internal and external markets.

The beginnings of the firm go back to 2003, when it began to manufacture vaccines for a Dutch laboratory after the appearance of the Bovine Spongiform Encephalopathy disease (the famous Mad Cow Disease) in the world. Then it launched its own brand on the market and today it is one of the leaders in its segment.

The administrative headquarters are located in Victoria, Buenos Aires province. It also has two properties in Flores and Mercedes. In the latter, a second plant is being built that will significantly increase the volume produced and it is estimated that it will come into operation during the second half of 2023.

The efficient logistics of product delivery allows Tecnovax to lead the local market for biological products for livestock (excluding foot-and-mouth disease), supplying more than 27% of the sector’s demand. The remaining market is distributed among national laboratories.

The firm’s growth strategy allowed it to expand into new niches such as the manufacture and sale of vaccines for salmonids abroad.

The commercialization of vaccines for livestock is carried out under the Providean brand, which satisfies a wide range of treatments for reproductive, respiratory, digestive and anti-rabies diseases. Regarding the segment of companion animals, Tecnovax participated this year in the tender of the Ministry of Health of the Nation for the delivery of anti-rabies vaccines for a total of 1,500,000 doses, which will allow it to position itself as a leading national producer in this treatment.

In companion animals, the company ranks third with 13% of the market, but at a national level it is the main producer. The sector is led by international laboratories such as Elanco, Boehringer Ingelheim, Zoetis, among others.

Regarding their income, 72% corresponds to vaccines for the livestock sector, 15% for companion animals and 13% for salmonids. Meanwhile, 81% of the total corresponds to sales in the domestic market, while the remaining 19% is sold abroad. Its exports are concentrated in Brazil, Chile, Colombia and Paraguay.

In its exercise closed in June 2022, it invoiced around 4,100 million pesos, and in its exercise for the six-month period closed last December it reached sales of more than 1,500 million.

In turn, according to the BCRA, its debt with local banks amounts to just over 1,220 million pesos, all in situation 1 (normal, without arrears in payments). 39% taken with HSBC, 20% with Santander and 16% with Galicia, the rest is distributed to a lesser extent among other entities.

Each of its founding partners, Diego La Torre, Matías Grosman and Nicolás Grosman, own 33% of the company’s shares and hold the positions of president, vice president and regular director, respectively. The partners have direct and indirect participation in companies located in Chile, Uruguay and Brazil, under the name of Tecnovax Chile SA, Tecnovax do Brasil Importaçao e Comercio de Produtos Veterinarios Ltda and Globax SA, all companies that distribute and market the company’s products. signature.

From the start-up of its new production plant, the company will not only grow in operational capacity but also aspires to grow in the markets where it is located. According to the project, its livestock viral vaccine -of which it currently produces 65 million units- will go on to produce 260 million units.

Of the Clostridial cattle vaccine, it will go from 144 million to 650 million. For pets attenuated from 3 million units to 23.4 million. At the same time for companion animals (rabies) it will grow from 10 million units to 26. The vaccine for brucellosis will go from 9.7 million units to 78 million units and finally for fish it will increase its production by 10 from the current 1.1 billion units.

This is an institutional video where this expansion tells:

Within this framework, the risk rating agency Moody’s expects a growth of around 50% in the volumes sold for the years 2024 and 2025 with sales between 25 and 35 million dollars, in line with the increase in its productive capacity.

The company’s strategy is to continue meeting the demand of the local market and strengthen sales in the foreign market, both in countries such as Brazil and New Zealand, where the brand’s positioning improves; as well as in new territories, mainly in the East, where the marketing licenses are in the approval process.